Home > Keywords >
Catalog | name | Description | price |
---|---|---|---|
R-R-2347 | LFM-A13 CAS No.62004-35-7 | LFM-A13/CAS No.62004-35-7 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research. | price> |
R-C-648 | AT7519HCL cas:902135-91-5 | AT7519 Hydrochloride is a potent inhibitor of CDKs,with IC50s of 210,47,100,13, 170,and <10 nM for CDK1,CDK2,CDK4 to CDK6,and CDK9,respectively. | price> |
R-R-2348 | (3R,4S)-Tofacitinib CAS No.1092578-46-5 | (3R,4S)-Tofacitinib/CAS No.1092578-46-5 is an less active enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM. | price> |
R-C-649 | StemRegenin 1 (SR1) CAS No. 1227633-49-9 | StemRegenin 1(SR1)is a cell-permeable purine derivative that acts as an antagonist of aryl hydrocarbon receptor and promotes the self-renewal of hematopoietic stem cells (HSCs). | price> |
R-R-2349 | Fosifidancitinib CAS No.1237168-58-9 | Fosifidancitinib/CAS No.1237168-58-9 is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases. | price> |
R-C-650 | KI8751 cas:228559-41-9 | Ki8751 is a cell-permeable quinolyloxyphenyl-urea compound that acts as a Flk-1 (VEGFR-2)-selective inhibitior in both cell-based and cell-free assays. | price> |
R-R-2350 | Nimucitinib CAS No.2740557-24-6 | Nimucitinib/CAS No.2740557-24-6 is a Janus kinase (JAK) inhibitor. | price> |
R-C-651 | Rociletinib (CO-1686) cas:1374640-70-6 | Rociletinib(CO-1686,AVL-301)is an irreversible,mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays,respectively. | price> |
R-R-2351 | (Rac)-Ruxolitinib-d9 CAS No.2469553-67-9 | (Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9)/CAS No.2469553-67-9 is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor. | price> |
R-C-652 | RGFP966 | RGFP966 is a highly selective HDAC3 inhibitor with an IC50 of 80 nM and shows no inhibition to other HDACs at concentrations up to 15 μM.RGFP966 can penetrate the blood brain barrier(BBB). | price> |
R-R-2352 | JAK-IN-25 CAS No.2127110-22-7 | JAK-IN-25 (compound 19)/CAS No.2127110-22-7 is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC50 of 28 nM. JAK-IN-25 has the potential for cancer research. | price> |
R-C-653 | AZD1080 cas:612487-72-6 | AZD1080 is a novel GSK3 inhibitor,rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. | price> |
R-R-2353 | Lepzacitinib CAS No.2321488-47-3 | Lepzacitinib/CAS No.2321488-47-3 is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases. | price> |
R-C-654 | tariquidar cas:206873-63-4 | Tariquidar(XR9576)is a potent and selective noncompetitive inhibitor of P-glycoprotein with Kd of 5.1 nM in CHrB30 cell line,reverses drug resistance in MDR cell Lines. | price> |
R-R-2354 | Dehydrocrenatidine CAS No.65236-62-6 | Dehydrocrenatidine/CAS No.65236-62-6, a natural alkaloid, is a specific JAK inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain. | price> |
R-C-655 | SKLB610 cas:1125780-41-7 | SKLB610 is a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. | price> |
R-R-2355 | Homoharringtonine CAS No.26833-87-4 | Homoharringtonine (Omacetaxine mepesuccinate;HHT)/CAS No.26833-87-4 is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation. | price> |
R-C-656 | Voxtalisib (XL765) CAS:934493-76-2 | Voxtalisib(XL765)is a potent PI3K inhibitor,which has a similar activity toward class I PI3K (IC50s=39,113,9 and 43 nM for p110α,p110β,p110γ and p110δ, respectively),also inhibits DNA-PK(IC50=150 nM) and mTOR(IC50=157 nM).Voxtalisib (XL765)inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively. | price> |
R-R-2356 | STAT6-IN-2 CAS No.1355594-85-2 | STAT6-IN-2 (Comp R-84)/CAS No.1355594-85-2 is an inhibitor of STAT6. STAT6-IN-2 inhibits the secretion of chemokine eliciting eosinophil infiltration eotaxin-3. STAT6-IN-2 can be used for immune disease research. | price> |
R-C-657 | ENMD2076 cas:934353-76-1 | ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM,25-fold selective for Aurora A than over Aurora B and less potent to RET,SRC,NTRK1/TRKA,CSF1R/FMS,VEGFR2/KDR,FGFR and PDGFRα.ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0.025 to 0.7 μM,which induces apoptosis and G2/M phase arrest. | price> |